Given the pronounced cardiac and vascular protective effect observed with a moderate reduction in blood pressure by Cmpd17b, a potential strategy that involves combining this agonist with clinical standard of care, such as an AT1 antagonist, could lead to synergistic improvement in attenuating hypertension-induced cardiovascular complications. This evidence concerns the gene AGTR1 and Hypertension.